| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | fulvestrant | CTRPv2 | pan-cancer | AAC | -0.11 | 0.2 |
| mRNA | tanespimycin:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.048 | 0.2 |
| mRNA | BRD-K51831558 | CTRPv2 | pan-cancer | AAC | -0.067 | 0.2 |
| mRNA | SGX-523 | CTRPv2 | pan-cancer | AAC | -0.047 | 0.2 |
| mRNA | necrostatin-7 | CTRPv2 | pan-cancer | AAC | -0.047 | 0.2 |
| mRNA | BRD-K45681478 | CTRPv2 | pan-cancer | AAC | 0.045 | 0.2 |
| mRNA | CIL41 | CTRPv2 | pan-cancer | AAC | -0.065 | 0.2 |
| mRNA | MG-132 | CTRPv2 | pan-cancer | AAC | 0.076 | 0.2 |
| mRNA | Erlotinib | UHNBreast | pan-cancer | AAC | -0.35 | 0.2 |
| mRNA | niclosamide | CTRPv2 | pan-cancer | AAC | -0.045 | 0.2 |